MK-677 (Ibutamoren) FAERS Safety Signals: What the Adverse-Event Data Actually Show

What MK-677 Is and Why It Lacks an FDA Label

MK-677, also known as ibutamoren mesylate, is an orally active, non-peptide ghrelin-receptor agonist that stimulates growth hormone (GH) release from the pituitary gland. It was developed by Merck Research Laboratories in the 1990s and progressed through Phase II clinical trials for conditions including GH deficiency, sarcopenia, and osteoporosis 1. Merck never submitted a New Drug Application (NDA) to the FDA, and development was discontinued.

Because no NDA was filed, MK-677 has no FDA-approved label, no prescribing information, and no post-marketing surveillance obligation 2. The compound now circulates through online "research chemical" vendors and gray-market supplement retailers. Without a label, every dose a consumer takes is pharmacologically uncharted territory. The FDA has stated that products marketed as selective androgen receptor modulators (SARMs) and related research chemicals "are not dietary supplements and are unapproved by FDA for human use" 3. That language applies equally to MK-677, even though it is technically a GH secretagogue rather than a SARM.

How FAERS Works and Why MK-677 Signals Are Hard to Capture

The FDA Adverse Event Reporting System collects voluntary safety reports on drugs marketed in the United States. FAERS serves as an early-warning system: once a drug reaches enough patients, statistical algorithms (such as the Empirical Bayesian Geometric Mean, or EBGM) flag disproportionate reporting of specific adverse events 2.

For MK-677, this system has a structural blind spot. FAERS depends on reports linked to a marketed drug product, ideally with an NDA or ANDA number. MK-677 has neither. Reports can still be filed under a generic compound name, but the reporting rate for unapproved research chemicals is extremely low. Consumers buying ibutamoren online rarely file MedWatch reports. Clinicians who encounter adverse reactions may not recognize the compound or may not know how to report it against a product that lacks a National Drug Code.

The result is that FAERS data for MK-677 almost certainly undercounts true adverse events by a large margin. What we know about its safety profile comes primarily from controlled clinical trials, not post-market surveillance 4.

Hyperglycemia and Insulin Resistance: The Dominant Safety Signal

The most consistent and clinically significant safety signal across MK-677 trials is impaired glucose metabolism. Growth hormone is a counter-regulatory hormone that opposes insulin action. Sustained GH elevation, whether from exogenous GH injections or from a secretagogue like ibutamoren, raises fasting glucose and reduces insulin sensitivity.

In the two-year randomized, double-blind trial by Nass et al. (2008), 65 healthy elderly adults received either MK-677 25 mg daily or placebo. Fasting blood glucose increased significantly in the MK-677 group, and HbA1c rose by a mean of 0.13 percentage points relative to placebo (P = 0.015) 4. Several subjects met criteria for new-onset impaired fasting glucose. The investigators noted that "the increase in fasting glucose was the most common reason for study discontinuation in the MK-677 group."

Murphy et al. (1998) observed similar metabolic changes over shorter durations. In their study of nine elderly subjects receiving MK-677 25 mg daily for four weeks, fasting insulin increased and insulin sensitivity decreased, even as GH pulsatility and IGF-1 levels rose by approximately 55% above baseline 1. The GH axis responded as designed. The glucose axis responded as predicted by decades of endocrinology.

For individuals already at risk of type 2 diabetes (a group that includes many older adults and many people with obesity, the very populations most likely to seek GH-related compounds for body composition), this signal is not subtle. The Endocrine Society's 2011 clinical practice guideline on GH use in adults explicitly warns that "GH replacement increases insulin resistance and may unmask previously undiagnosed impaired glucose tolerance or diabetes" 5. MK-677 produces GH elevations comparable to replacement doses, and the same metabolic trade-off applies.

Edema, Appetite Stimulation, and Musculoskeletal Complaints

Beyond glucose metabolism, three additional safety signals appear repeatedly in MK-677 trial data.

Peripheral edema occurred in roughly 12 to 50% of MK-677-treated subjects across published trials, depending on dose and population 1 4. The mechanism is straightforward: GH promotes sodium and water retention through direct renal tubular effects. Most cases were mild and self-limiting, but in elderly subjects or those with borderline cardiac function, fluid retention carries clinical weight.

Appetite stimulation is pharmacologically expected. MK-677 is a ghrelin mimetic. Ghrelin is the primary orexigenic hormone. In the Chapman et al. (1996) study, subjects receiving a single oral dose of MK-677 showed significant increases in caloric intake over 24 hours compared to placebo 6. For individuals using MK-677 with the goal of fat loss, this effect works directly against their objective.

Musculoskeletal complaints, including joint stiffness and myalgia, were reported in multiple trials and are consistent with the known side-effect profile of GH excess 4. In the Nass et al. two-year trial, muscle pain and joint swelling appeared more frequently in the treatment arm, though rates were not always statistically separated from placebo at the published sample size.

What the Published Trial Data Tell Us That FAERS Cannot

Because FAERS is structurally limited for unapproved compounds, the published clinical trial database is the primary evidence source. Three trials carry the most weight.

Murphy et al. (1998) studied nine older adults (ages 64-81) given MK-677 25 mg daily for 28 days. GH secretion increased to levels seen in young adults. IGF-1 rose 55% above baseline. Fasting glucose increased. Fat-free mass increased by 1.0 kg on average. The study confirmed biological activity but raised early flags on glucose handling 1.

Nass et al. (2008) remains the longest controlled MK-677 trial. Over two years, 65 healthy elderly subjects received 25 mg daily or placebo. GH and IGF-1 increased to youthful levels and remained elevated throughout the study. Fat-free mass increased by 1.6 kg at year one. Body weight increased by 2.7 kg, with fat mass also rising. Fasting glucose rose. The authors concluded that while MK-677 "effectively reverses the somatopause," the metabolic trade-offs limit its clinical utility 4.

Svensson et al. (1998) examined MK-677 in obese males over eight weeks at doses of 5 mg and 25 mg daily. The 25 mg dose increased IGF-1 by approximately 40% and GH secretion by 82%. Fat-free mass increased by a mean of 2.7 kg. Respiratory quotient decreased, suggesting a shift toward fat oxidation, but total body weight also increased due to fluid retention 7. Fasting glucose changes were not statistically significant in this shorter trial, but the trend was consistent with other datasets.

Across all three trials, the pattern is the same: MK-677 reliably raises GH and IGF-1, modestly increases lean mass, and consistently nudges glucose metabolism in the wrong direction. No trial demonstrated sustained fat loss.

Regulatory Status: Not Approved, Not Controlled, Not Safe by Default

MK-677 occupies a regulatory gray zone. It is not a Schedule III controlled substance (unlike anabolic steroids). It is not classified as a dietary supplement under DSHEA, because it was never sold as a food product before 1994 and is a novel synthetic compound. And it has no FDA approval for human use 3.

The FDA has taken enforcement action against companies marketing similar unapproved compounds. In November 2017, the agency issued a public advisory stating: "We are extremely concerned about unscrupulous companies marketing body-building products with potentially dangerous ingredients" 3. Warning letters have been sent to vendors selling SARMs and GH secretagogues without approved NDAs. The SARMs Control Act, introduced in the U.S. Congress multiple times since 2018, would add compounds like MK-677 to the Controlled Substances Act, though it has not yet been enacted as of May 2026 8.

In the European Union, MK-677 has no European Medicines Agency (EMA) authorization. Australia's Therapeutic Goods Administration (TGA) classifies it as a prohibited import. The World Anti-Doping Agency (WADA) includes ibutamoren on its prohibited list under the category of GH-releasing factors.

Specific Risks for Common MK-677 Consumer Profiles

The people most likely to purchase MK-677 online fall into a few overlapping groups: middle-aged adults seeking anti-aging effects, bodybuilders pursuing lean mass, and individuals with sleep complaints who have read that GH secretagogues increase slow-wave sleep.

For middle-aged and older adults, the glucose signal is the primary concern. The American Diabetes Association's Standards of Care note that adults over 45 with a BMI above 25 should already be screened for prediabetes 9. Adding a compound that raises fasting glucose and HbA1c to this population, without physician monitoring, is a setup for undetected metabolic harm.

For bodybuilders, the appetite-stimulating effect and the water retention complicate the typical cutting-phase goal. The modest lean mass gains observed in trials (1.0 to 2.7 kg over weeks to months) are not dramatically different from what structured resistance training alone produces.

For sleep optimization, while MK-677 does appear to increase Stage IV sleep duration in limited studies, the metabolic cost of nightly GH secretagogue dosing has not been evaluated against safer, evidence-based sleep interventions 10.

Contaminant Risk and Dose Uncertainty in Unregulated Products

A safety signal that FAERS will never capture is contamination. MK-677 sold through online vendors is not manufactured under FDA-inspected Current Good Manufacturing Practice (cGMP) conditions. Independent analyses of "research chemical" products have repeatedly found dose inaccuracies, unlisted active ingredients, and heavy metal contamination 3.

A consumer who believes they are taking 10 mg of ibutamoren may be receiving 5 mg, 20 mg, or an entirely different compound. Without analytical testing, dose-response assumptions based on published clinical trials are unreliable. The adverse events reported in those trials occurred under carefully manufactured, analytically verified compound. Gray-market products do not meet that standard.

How Clinicians Should Counsel Patients Who Ask About MK-677

A patient who mentions MK-677 is often already taking it. Confrontation is less effective than a direct review of what the evidence shows. The conversation should cover three points: (1) the compound reliably raises GH and IGF-1, confirming it "works" in the narrow pharmacological sense; (2) the clinical benefit in terms of body composition is modest and accompanied by glucose and fluid-related trade-offs; and (3) the product they purchased has no quality assurance.

Baseline and follow-up labs should include fasting glucose, HbA1c, IGF-1, fasting insulin, and a comprehensive metabolic panel. If glucose is already impaired, the recommendation to discontinue is straightforward.

For patients interested in GH axis optimization through safer, evidence-based routes, adequate sleep duration (7-9 hours), high-intensity resistance training, and body fat reduction to <25% all independently raise endogenous GH secretion without the metabolic penalty of a pharmacological secretagogue 5.

The fasting glucose increase observed in Nass et al.'s two-year trial (HbA1c +0.13%, P = 0.015) occurred in healthy subjects 4. In a patient with a baseline HbA1c of 5.6%, that shift alone could cross the 5.7% threshold into prediabetes.